191 related articles for article (PubMed ID: 37607227)
21. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
Hägerbrand K; Varas L; Deronic A; Nyesiga B; Sundstedt A; Ljung L; Sakellariou C; Werchau D; Thagesson M; Gomez Jimenez D; Greiff L; Celander M; Smedenfors K; Rosén A; Bölükbas D; Carlsson F; Levin M; Säll A; von Schantz L; Lindstedt M; Ellmark P
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323431
[TBL] [Abstract][Full Text] [Related]
22. Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy.
Enell Smith K; Deronic A; Hägerbrand K; Norlén P; Ellmark P
Expert Opin Biol Ther; 2021 Dec; 21(12):1635-1646. PubMed ID: 34043482
[No Abstract] [Full Text] [Related]
23. PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8
Chaib M; Sipe LM; Yarbro JR; Bohm MS; Counts BR; Tanveer U; Pingili AK; Daria D; Marion TN; Carson JA; Thomas PG; Makowski L
Cancer Lett; 2022 Apr; 531():98-108. PubMed ID: 35074498
[TBL] [Abstract][Full Text] [Related]
24. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses.
Murphy WJ; Welniak L; Back T; Hixon J; Subleski J; Seki N; Wigginton JM; Wilson SE; Blazar BR; Malyguine AM; Sayers TJ; Wiltrout RH
J Immunol; 2003 Mar; 170(5):2727-33. PubMed ID: 12594303
[TBL] [Abstract][Full Text] [Related]
25. Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy.
Beckmann K; Reitinger C; Yan X; Carle A; Blümle E; Jurkschat N; Paulmann C; Prassl S; Kazandjian LV; Loré K; Nimmerjahn F; Fischer S
Antibodies (Basel); 2024 Apr; 13(2):. PubMed ID: 38651411
[TBL] [Abstract][Full Text] [Related]
26. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
White AL; Dou L; Chan HT; Field VL; Mockridge CI; Moss K; Williams EL; Booth SG; French RR; Potter EA; Butts C; Al-Shamkhani A; Cragg MS; Verbeek JS; Johnson PW; Glennie MJ; Beers SA
J Immunol; 2014 Aug; 193(4):1828-35. PubMed ID: 25024386
[TBL] [Abstract][Full Text] [Related]
27. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.
Liu C; Lewis CM; Lou Y; Xu C; Peng W; Yang Y; Gelbard AH; Lizée G; Zhou D; Overwijk WW; Hwu P
J Immunother; 2012 Apr; 35(3):276-82. PubMed ID: 22421945
[TBL] [Abstract][Full Text] [Related]
28. Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.
Westwood JA; Darcy PK; Guru PM; Sharkey J; Pegram HJ; Amos SM; Smyth MJ; Kershaw MH
J Transl Med; 2010 Apr; 8():42. PubMed ID: 20426873
[TBL] [Abstract][Full Text] [Related]
29. A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.
Ma HS; Poudel B; Torres ER; Sidhom JW; Robinson TM; Christmas B; Scott B; Cruz K; Woolman S; Wall VZ; Armstrong T; Jaffee EM
Cancer Immunol Res; 2019 Mar; 7(3):428-442. PubMed ID: 30642833
[TBL] [Abstract][Full Text] [Related]
30. Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility.
Liu X; Zhao Y; Shi H; Zhang Y; Yin X; Liu M; Zhang H; He Y; Lu B; Jin T; Li F
Nat Commun; 2019 Sep; 10(1):4206. PubMed ID: 31562320
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses.
Kelsall BL; Stüber E; Neurath M; Strober W
Ann N Y Acad Sci; 1996 Oct; 795():116-26. PubMed ID: 8958922
[TBL] [Abstract][Full Text] [Related]
32. Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.
Ishihara J; Ishihara A; Potin L; Hosseinchi P; Fukunaga K; Damo M; Gajewski TF; Swartz MA; Hubbell JA
Mol Cancer Ther; 2018 Nov; 17(11):2399-2411. PubMed ID: 30097487
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
[TBL] [Abstract][Full Text] [Related]
34. Cell targeting and immunostimulatory properties of a novel Fcγ-receptor-independent agonistic anti-CD40 antibody in rhesus macaques.
Yan X; Ols S; Arcoverde Cerveira R; Lenart K; Hellgren F; Ye K; Cagigi A; Buggert M; Nimmerjahn F; Falkesgaard Højen J; Parera D; Pessara U; Fischer S; Loré K
Cell Mol Life Sci; 2023 Jun; 80(7):189. PubMed ID: 37353664
[TBL] [Abstract][Full Text] [Related]
35. Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects.
Welniak LA; Shorts L; Subleski J; Blazar BR; Wiltrout RH; Murphy WJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):534-9. PubMed ID: 15282531
[TBL] [Abstract][Full Text] [Related]
36. Anti-CD40-induced inflammatory E-cadherin+ dendritic cells enhance T cell responses and antitumour immunity in murine Lewis lung carcinoma.
Zhang Y; Hu X; Hu Y; Teng K; Zhang K; Zheng Y; Hong X; Yu K; Wang Y; Liu L
J Exp Clin Cancer Res; 2015 Feb; 34(1):11. PubMed ID: 25651850
[TBL] [Abstract][Full Text] [Related]
37. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
J Virol; 2017 May; 91(9):. PubMed ID: 28202751
[TBL] [Abstract][Full Text] [Related]
38. Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.
Newton MR; Askeland EJ; Andresen ED; Chehval VA; Wang X; Askeland RW; O'Donnell MA; Luo Y
Clin Exp Immunol; 2014 Jul; 177(1):261-8. PubMed ID: 24593764
[TBL] [Abstract][Full Text] [Related]
39. TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy.
Stone ML; Lee J; Herrera VM; Graham K; Lee JW; Huffman A; Coho H; Tooker E; Myers MI; Giannone M; Li Y; Buckingham TH; Long KB; Beatty GL
JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34101617
[TBL] [Abstract][Full Text] [Related]
40. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
Muik A; Adams 3rd HC; Gieseke F; Altintas I; Schoedel KB; Blum JM; Sänger B; Burm SM; Stanganello E; Verzijl D; Spires VM; Vascotto F; Toker A; Quinkhardt J; Fereshteh M; Diken M; Satijn DPE; Kreiter S; Ahmadi T; Breij ECW; Türeci Ö; Sasser K; Sahin U; Jure-Kunkel M
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
